Positron Emission Tomography and Positron Emission Tomography-CT Evaluation for Recurrent Papillary Thyroid Carcinoma: Meta-analysis and Literature Review

Overview

Journal Head Neck

Specialties General Surgery
Oncology

Date 2010 Jul 29

PMID 20665734

Citations 13

Authors

Mia E Miller

Qiaolin Chen

David Elashoff

Elliot Abemayor

Maie St John

Affiliations

Soon will be listed here.

Abstract

Background: Sensitivity and specificity data regarding positron emission tomography (PET) and PET/CT for surveillance of well-differentiated thyroid cancer does not evaluate subtypes separately. Papillary and follicular thyroid carcinoma may have different characteristics on PET/CT imaging and so should be investigated individually.

Methods: This is a systematic meta-analysis of studies using PET for surveillance in patients with papillary thyroid carcinoma.

Results: Using different statistical models, combined sensitivity of PET and PET/CT for papillary thyroid carcinoma was 77% by the fixed effect model and 82% by the random-effects model, specificity was calculated as 85% and 84%, respectively. Meta-regression was performed to evaluate whether I-131 negativity affected PET positivity; no correlation between I-131 negativity and PET sensitivity or specificity was found.

Conclusion: PET and PET/CT are useful modalities in surveillance of papillary thyroid carcinoma. To our knowledge, this is the first study to examine papillary thyroid carcinoma independently of other subtypes of well-differentiated thyroid carcinoma.

Citing Articles

The Role of Positron Emission Tomography/Computed Tomography in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives.

Panagiotidis E, Zhang-Yin J J Clin Med. 2024; 13(22).

PMID: 39598062 PMC: 11595340. DOI: 10.3390/jcm13226918.

Papillary thyroid cancer with suspicious uterine cervix metastasis: a case report and literature review.

Kim M, Jung H, Park C Gland Surg. 2022; 11(7):1270-1278.

PMID: 35935566 PMC: 9346220. DOI: 10.21037/gs-22-210.

Personalized Diagnosis in Differentiated Thyroid Cancers by Molecular and Functional Imaging Biomarkers: Present and Future.

Teodoriu L, Leustean L, Ungureanu M, Bilha S, Grierosu I, Matei M Diagnostics (Basel). 2022; 12(4).

PMID: 35453992 PMC: 9030409. DOI: 10.3390/diagnostics12040944.

Molecular Imaging and Theragnostics of Thyroid Cancers.

Giovanella L, Deandreis D, Vrachimis A, Campenni A, Petranovic Ovcaricek P Cancers (Basel). 2022; 14(5).

PMID: 35267580 PMC: 8909041. DOI: 10.3390/cancers14051272.

Prognostic Role of 2-[F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative I WBS and Positive 2-[F]-FDG PET/CT.

Albano D, Dondi F, Mazzoletti A, Bellini P, Rodella C, Bertagna F Diagnostics (Basel). 2021; 11(12).

PMID: 34943426 PMC: 8700137. DOI: 10.3390/diagnostics11122189.